DXCM - DexCom, Inc.
DexCom, Inc.
6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com
Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 7 500
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Kevin Ronald Sayer | Exec. Chairman, CEO & Pres | 2,22M | S.O. | 1958 |
| Mr. Jereme M. Sylvain | Exec. VP, CFO & Chief Accounting Officer | 841,14k | S.O. | 1980 |
| Mr. Jacob Steven Leach | Exec. VP & COO | 994,13k | S.O. | 1978 |
| Mr. Girish Naganathan | Exec. VP & CTO | 423,92k | S.O. | 1977 |
| Mr. Michael Jon Brown | Exec. VP & Chief Legal Officer | 954,46k | S.O. | 1970 |
| Mr. Shelly Ramasamy Selvaraj | Sr. VP & Chief Information Officer | S.O. | S.O. | 1959 |
| Mr. Sean Christensen | Director of Corp. Affairs & Head of Investor Relations | S.O. | S.O. | S.O. |
| Mr. Matthew Dolan | Exec. VP of Strategy, Corp. Devel. & Dexcom Labs | S.O. | S.O. | 1981 |
| Ms. Sadie M. Stern | Exec. VP & Chief HR Officer | S.O. | S.O. | 1975 |
| Mr. Andrew K. Balo | Exec. VP of Global Medical Affairs, Access & Evidence | S.O. | S.O. | 1948 |
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Gouvernance d’entreprise
L’ISS Governance QualityScore de DexCom, Inc. en date du 1 juin 2023 est 4. Les scores principaux sont Audit : 1; Société : 9; Droits des actionnaires : 6; Compensation : 2.
